A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00411515|
Recruitment Status : Completed
First Posted : December 14, 2006
Last Update Posted : December 15, 2006
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
|Condition or disease||Intervention/treatment||Phase|
|Corneal Transplantation||Drug: Mycophenolate Mofetil 2x 1g||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00411515
|University Eye hospital|
|Freiburg, Germany, 79106|
|Study Chair:||Thomas Reinhard, Prof. MD||University Eye Hospital, Freiburg|